CO4700452A1 - Derivados de indol - Google Patents

Derivados de indol

Info

Publication number
CO4700452A1
CO4700452A1 CO96009937A CO96009937A CO4700452A1 CO 4700452 A1 CO4700452 A1 CO 4700452A1 CO 96009937 A CO96009937 A CO 96009937A CO 96009937 A CO96009937 A CO 96009937A CO 4700452 A1 CO4700452 A1 CO 4700452A1
Authority
CO
Colombia
Prior art keywords
alkyl
represents hydrogen
dialkylamino
alkylamino
integer
Prior art date
Application number
CO96009937A
Other languages
English (en)
Inventor
Nadia Conti
Fabio Romano Di
Magistris Elisabetta De
Aldo Feriani
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of CO4700452A1 publication Critical patent/CO4700452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I)o una sal, o éster metabólicamente lábil del mismo, caracterizado porque R representa un grupo seleccionado de halógeno, alquilo, alcoxi, amino, alquilamino, dialquilamino, hidroxilo, trifluorometilo, trifluorometoxi, nitro, ciano, SO2 R4 , ó COR4 , en donde R4 representa hidroxilo, metoxi, amino, alquilamino o dialquilamino; m es cero o un número entero 1 ó 2: A representa una grupo etinilo o etenilo opcionalmente susbtituido; R1 representa hidrógeno o un grupo de alquilo, cicloalquilo, arilo o heterocíclico, opcionalmente substituidos; R2 representa hidrógeno o alquilo; o R1 y R2 junto con el átomo de nitrógeno al cual están unidos representan un anillo heterocíclico de 5 a 7 miembros, el cual puede contener un heteroátomo adicional seleccionado de oxígeno, azufre o nitrógeno; R3 representa hidrógeno o alquilo; n es cero o un número entero de 1 a 4. X = O ó S.
CO96009937A 1995-03-04 1996-03-01 Derivados de indol CO4700452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9504361.8A GB9504361D0 (en) 1995-03-04 1995-03-04 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
CO4700452A1 true CO4700452A1 (es) 1998-12-29

Family

ID=10770638

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96009937A CO4700452A1 (es) 1995-03-04 1996-03-01 Derivados de indol

Country Status (23)

Country Link
US (1) US5919811A (es)
EP (1) EP0813524A1 (es)
JP (1) JPH11501041A (es)
KR (1) KR19980702735A (es)
CN (1) CN1182417A (es)
AR (1) AR002711A1 (es)
AU (1) AU708291B2 (es)
BR (1) BR9607346A (es)
CA (1) CA2214583A1 (es)
CO (1) CO4700452A1 (es)
CZ (1) CZ277997A3 (es)
EA (1) EA000308B1 (es)
GB (1) GB9504361D0 (es)
HU (1) HUP9801838A3 (es)
IL (1) IL117331A (es)
MX (1) MX9706605A (es)
NO (1) NO309323B1 (es)
NZ (1) NZ303200A (es)
PE (1) PE62396A1 (es)
PL (1) PL322084A1 (es)
TW (1) TW438773B (es)
WO (1) WO1996027588A1 (es)
ZA (1) ZA961697B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
MXPA05007513A (es) * 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2009035927A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Bis-cyclyl substitued ureas or amides as soluble epoxide hydrolase inhibitors
PE20091101A1 (es) 2007-12-18 2009-07-26 Pharminox Ltd AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO
BRPI1011822A2 (pt) 2009-06-23 2016-03-29 Pharminox Ltd "compostos de 3-substituída-8-substituída-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona e sua aplicação"
US20130012706A1 (en) 2010-03-01 2013-01-10 Pharminox Limited Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
WO2012085501A1 (en) 2010-12-20 2012-06-28 Pharminox Limited 8 - sulfo - imidazotetrazin- 4 - one compounds and their use as anticancer drug
TW202128630A (zh) 2019-11-11 2021-08-01 荷蘭商卡普三世責任有限公司 工業規模上用於生產ε-己內醯胺及硫酸銨之方法及設備

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AR002711A1 (es) 1998-04-29
PE62396A1 (es) 1997-01-11
NO974043D0 (no) 1997-09-03
ZA961697B (en) 1997-10-01
EP0813524A1 (en) 1997-12-29
IL117331A0 (en) 1996-07-23
NO309323B1 (no) 2001-01-15
US5919811A (en) 1999-07-06
BR9607346A (pt) 1997-12-30
AU4943896A (en) 1996-09-23
EA000308B1 (ru) 1999-04-29
WO1996027588A1 (en) 1996-09-12
NO974043L (no) 1997-11-03
JPH11501041A (ja) 1999-01-26
KR19980702735A (ko) 1998-08-05
MX9706605A (es) 1998-02-28
AU708291B2 (en) 1999-07-29
HUP9801838A3 (en) 2000-04-28
CN1182417A (zh) 1998-05-20
HUP9801838A2 (hu) 1998-12-28
IL117331A (en) 2000-06-29
TW438773B (en) 2001-06-07
CZ277997A3 (cs) 1998-06-17
GB9504361D0 (en) 1995-04-26
CA2214583A1 (en) 1996-09-12
EA199700160A1 (ru) 1998-02-26
PL322084A1 (en) 1998-01-05
NZ303200A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
CO4700452A1 (es) Derivados de indol
ECSP941146A (es) Derivados de benzofurano
CO4900066A1 (es) Derivados de tetrahidroquinolina
ES2185338T3 (es) Derivados de fumagilol y procedimientos para su fabricacion.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
CA2236814A1 (en) Quinoline and quinazoline compounds useful in therapy
YU31699A (sh) Hinolin i hinazolin jedinjenja korisna u terapiji,naročito u tretmanu benigne hiperplazije prostate
DE69325454T2 (de) Taxol-derivate
CO5060482A1 (es) Derivados terapeuticos de biarilo
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
CO4290355A1 (es) Derivados de indol
AR005233A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina, procesos para su preparacion, una composicion farmaceutica y el uso en la elaboracion de un medicamento
DK0875506T3 (da) Quinolin- og quinazolin-forbindelser, som er anvendelige til behandling
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DE69202120T2 (de) Harnstoffderivate, ihre Herstellung und ihre Verwendung bei der Therapie.
DK304289A (da) Benzenderivater
KR970702848A (ko) 아릴피페리딘 및 아릴피페라진 유도체 및 이를 함유하는 약제(Arylpiperidine and arylpiperazine derivatives and drugs containing the same)
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
AU539177B2 (en) Amino alkoxy pyrazoles
TR199801366T2 (en) �zooksasefem t�revleri.
DE3781783D1 (de) N-alkyl-derivate von 2-amino-6,7-dimethoxytetralin, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen mit antihypertensiver wirkung.
KR900011764A (ko) 치환된 벤조[b]피란, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제
AR045154A1 (es) Compuestos piperidinicos 1,4-disustituidos, su preparacion, composiciones que los contienen, y su uso
EP1116486A4 (en) MEDICAL COMPOSITION CONTAINING NITROETHENAMINE DERIVATIVES OR SALTS AS ACTIVE INGREDIENTS
CO4940434A1 (es) Derivados terapeuticos de naftaleno